drotebanol

Drotebanol is a synthetic opioid analgesic of the morphinan class that acts as an opioid agonist at mu-opioid receptors. It was developed by Sankyo Company in Japan during the 1970s and is synthesized from thebaine. Drotebanol exhibits potent antitussive (cough suppressant) effects—approximately ten times more potent than codeine—and has analgesic properties several times stronger than codeine but weaker than morphine. It was previously marketed under the brand name Metebanyl for cough suppression and pain relief but is no longer used in medicine. Drotebanol has a risk of dependence and abuse typical of opioids and is classified as a Schedule I controlled substance in the United States[1][3][5][7].

Brand names

Metebanyl

Other names

OxymethebanolMetebanyl14-Hydroxy-6-beta-thebainol 4-methyl etherDihydro-14-hydroxy-4-O-methyl-6-beta-thebainolDihydro14-hydroxy-4-O-methyl-6-beta-thebainolDihydro 14-hydroxy-4-O-methyl-6-beta-thebainol14-Hydroxydihydro-6-beta-thebainol 4-methyl ether3,4-dimethoxy-17-methylmorphinan-6 beta,14-diol3,4-Dimethoxy-17-methylmorphinan-6-beta,14-diol